Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
493.60    -5.80 (-1.16%)
Bid:
492.80
Ask:
493.80
Spread: 1.00 (0.203%)
Market Cap: £1.34b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Contract Win

29 Sep 2016 10:53

RNS Number : 2040L
Chemring Group PLC
29 September 2016
 

FOR IMMEDIATE RELEASE 29 SEPTEMBER 2016

 

ELECTRONIC WARFARE CONTRACT WIN

 

Chemring Group PLC ("Chemring" or "the Group"), is pleased to announce that its subsidiary Chemring Australia has been awarded an A$18 million contract by the Australian Department of Defence to supply Chemring's Resolve 3 electronic warfare manpack system.

 

Resolve 3 is the latest iteration of the highly successful, combat-proven, Resolve electronic surveillance system, designed and produced by UK-based Chemring Technology Solutions. Up to 50 man-portable systems will be delivered during the first 18 months of the contract, with the systems being assembled at Chemring Australia's facility at Mulgrave, Victoria.

 

Michael Flowers, Group Chief Executive of Chemring, commented: "Resolve 3 represents the latest in man-portable electronic surveillance capability and I am delighted that Chemring Australia has won this contract. This is the largest award that the Group has received for the Resolve system, growing Resolve's user-base to nine countries and builds on Chemring's position as a market leader in electronic warfare."

-ENDS-

 

For further information:

 

Michael Flowers Group Chief Executive, Chemring Group PLC 01794 833901

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

James White MHP Communications 0203 128 8100

 

Cautionary statement

 

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

About Chemring Group

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALLMLTMBITMLF
Date   Source Headline
2nd Dec 20247:00 amRNSTotal Voting Rights
14th Nov 20247:19 amRNSDirector Declaration
6th Nov 20247:15 amRNSDirector Declaration
4th Nov 20247:00 amRNS£278m Contract Wins
1st Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20247:00 amRNSTransaction in Own Shares
17th Oct 20247:00 amRNSTrading Update
14th Oct 202412:29 pmRNSHolding(s) in Company
1st Oct 20247:00 amRNSTotal Voting Rights
2nd Sep 20247:00 amRNSTotal Voting Rights
16th Aug 202410:10 amRNSAdditional Listing
5th Aug 202410:03 amRNSDirector/PDMR Shareholding
1st Aug 20247:00 amRNSTotal Voting Rights
18th Jul 20242:34 pmRNSDirector Declaration
1st Jul 20247:00 amRNSTotal Voting Rights
24th Jun 20247:00 amRNSAppointment of Chairman-designate
19th Jun 20247:00 amRNSBlock listing update
18th Jun 20247:00 amRNSBlock listing Interim Review
10th Jun 20247:00 amRNSContract Award
4th Jun 20247:00 amRNSHalf-year Report
3rd Jun 20247:00 amRNSTotal Voting Rights
1st May 202411:29 amRNSTotal Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:13 amRNSTotal Voting Rights
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSFunding Awards
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 202412:45 pmRNSResult of AGM
23rd Feb 20247:00 amRNSAGM Update
16th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.